EDETATE CALCIUM DISODIUM ANHYDROUS

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H12N2O8.Ca.2Na
Molecular Weight	374.268
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of EDETATE CALCIUM DISODIUM ANHYDROUS

SMILES

[Na+].[Na+].[Ca++].[O-]C(=O)CN(CCN(CC([O-])=O)CC([O-])=O)CC([O-])=O

InChI

InChIKey=SHWNNYZBHZIQQV-UHFFFAOYSA-J

InChI=1S/C10H16N2O8.Ca.2Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;;/q;+2;2*+1/p-4

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count	MOL RATIO 2 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H12N2O8
Molecular Weight	288.2109
Charge	-4
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	Ca
Molecular Weight	40.078
Charge	2
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Calcium lactate is the salt that consists of two lactate anions for each calcium cation (Ca2+); this salt is used as a calcium supplement to treat hypocalcemia. However, as a source of free calcium, this salt is less convenient than calcium citrate. Calcium lactate inhalation powder also called as PUR118 participated in phase I clinical trials to determine whether this formulation was safe and tolerable in a population of subjects with Cystic Fibrosis (CF). PUR118 also was used in another clinical trials to evaluate its effect on ozone-induced airway Inflammation in healthy normal volunteers in case of Chronic Obstructive Pulmonary Disease (COPD). The obtained results revealed that PUR118 reduced the severity of acute exacerbations in COPD and CF and had the beneficial impacts on mortality, morbidity, and quality of life in affected individuals. However, both studies were discontinued.

Originator

Approval Year

Conditions

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2,578
Hypocalcemia 75	Primary	Not Provided 504	Unknown
Chronic obstructive pulmonary disease 174	Palliative	Phase I 428	Unknown
Cystic fibrosis 120	Palliative	Phase I 428	Unknown
Unknown 2,578
Hypocalcemia 75	Primary	Approved 8,429	Unknown

PubMed

Show entries

Title	Date	PubMed
Effects of a calcium receptor activator on the cellular response to calcium in human keratinocytes.	1999 Sep	10469331
Discovery of CP-199,330 and CP-199,331: two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity.	1999 Sep 20	10509933
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.	2000 Jan 7	10617657
Hepatocyte growth factor disrupts cell contact and stimulates an increase in type 3 inositol triphosphate receptor expression, intracellular calcium levels, and apoptosis of rat ovarian surface epithelial cells.	2000 Jun	10963052
Characterization of the human cysteinyl leukotriene 2 receptor.	2000 Sep 29	10851239

Showing 1 to 5 of 20 entries

Previous1 2 3 4Next

Patents

Sample Use Guides

In Vivo Use Guide

Proper administration of calcium carbonate or phosphate: Taking tablets 1 to 11/2 hours after meals, unless otherwise directed by physician. Recommended doses for adolescents and adults is 800-1200 mg/day; for pregnat orbreast-feeding females 1200 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Unknown